Polaryx Therapeutics financials
$2.07+1.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$1.4M | -$2.0M |
| Net income | -$1.4M | -$2.5M |
| Net margin | — | — |
| Diluted EPS | $-0.03 | $-0.05 |
| EBITDA | -$1.4M | -$2.0M |
| Operating cash flow | -$1.4M | -$2.1M |
| Free cash flow | -$1.4M | -$2.1M |
| Diluted shares | 48.3M | 47.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $11.5M | $3.1M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $11.8M | $3.5M |
| Total liabilities | $873.0K | $1.0M |
| Shareholders' equity | $10.9M | $2.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology